Patent Highlights June-July 2023.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Patent highlights February-March 2023.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Patent highlights October-November 2022.

A snapshot of recent noteworthy developments in the patent literature of relevance to pharmaceutical and medical research and development.

Patent Highlights June-July 2022.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Patent Highlights April - May 2022.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Patent highlights December 2021-January 2022.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Patent highlights February-March 2022.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Patent highlights October-November 2021.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Patent highlights August-September 2021.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology.

Mechanism-based therapy centred on the molecular understanding of disease-causing pathways in a given patient is still the exception rather than the rule in medicine, even in cardiology. However, recent successful drug developments centred around the second messenger cyclic guanosine-3'-5'-monophosphate (cGMP), which is regulating a number of cardiovascular disease modulating pathways, are about to provide novel targets for such a personalized cardiovascular therapy. Whether cGMP breakdown is inhibited or cGMP synthesis is stimulated via guanylyl cyclases or their upstream regulators in different cardiovascular disease phenotypes, the outcomes seem to be so far uniformly protective. Thus, a network of cGMP-modulating drugs has evolved that act in a mechanism-based, possibly causal manner in a number of cardiac conditions. What remains a challenge is the detection of cGMPopathy endotypes amongst cardiovascular disease phenotypes. Here, we review the growing clinical relevance of cGMP and provide a glimpse into the future on how drugs interfering with this pathway may change how we treat and diagnose cardiovascular diseases altogether.

Patent highlights June-July 2021.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Patent highlights February-March 2021.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Patent highlights December 2020-January 2021.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Patent highlights October-November 2020.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.